Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • United States Judge delays cannabis rescheduling hearings ...
  • Germany Divide over cannabis seen in party manifestos ahead of elections ...
  • Ukraine Cannabis extract registered in the State Register of Medicinal Products ...
  • Belgium Positive list of notified herbal products for smoking is updated ...
  • Ireland Cannabis discussed in government formation talks ...
  • Illinois - United States Four new conditions added to eligibility list for medical cannabis ...
  • Czech Republic Implementation delayed of ‘psychomodulating substances’ regulation ...
  • Ukraine First cannabis-based medicines officially registered ...
  • Illinois - United States Delta-8 bill fails to pass despite Senate support ...
  • United States Congress passes one-year extension of Farm Bill ...
  • Tennessee - United States Temporary block to state rules that would have banned hemp products ...
  • Luxembourg Tilray appointed sole supplier of medical cannabis programme ...
View all
News analysis

Will FDA draw a line between other CBD products and pharmaceuticals?

Written by || 29th April 2019 || News analysis | Health and science | Regulation and legislation | GeographiesNorth America United States

The US FDA is to hold a public hearing on 31st May on the safety of products containing cannabis or cannabis-derived compounds ― and stakeholders will be looking for a dividing line
Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.